Kura Oncology, Inc. (NASDAQ:KURA) Holdings Trimmed by Bank of New York Mellon Corp

Bank of New York Mellon Corp lowered its position in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 1.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 200,812 shares of the company’s stock after selling 2,129 shares during the quarter. Bank of New York Mellon Corp’s holdings in Kura Oncology were worth $1,325,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of KURA. Corient Private Wealth LLC bought a new position in Kura Oncology during the fourth quarter valued at about $109,000. Thrivent Financial for Lutherans bought a new position in Kura Oncology during the fourth quarter valued at about $250,000. Teacher Retirement System of Texas lifted its holdings in shares of Kura Oncology by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company’s stock valued at $120,000 after purchasing an additional 2,285 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Kura Oncology by 101.6% during the fourth quarter. American Century Companies Inc. now owns 66,706 shares of the company’s stock valued at $581,000 after purchasing an additional 33,612 shares during the last quarter. Finally, Sei Investments Co. lifted its holdings in shares of Kura Oncology by 41.0% during the fourth quarter. Sei Investments Co. now owns 20,815 shares of the company’s stock valued at $181,000 after purchasing an additional 6,055 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have recently commented on KURA shares. JMP Securities reaffirmed a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a report on Wednesday, June 4th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a report on Monday, April 28th. Barclays reduced their target price on Kura Oncology from $32.00 to $11.00 and set an “overweight” rating for the company in a report on Friday, May 2nd. Wall Street Zen downgraded Kura Oncology from a “buy” rating to a “hold” rating in a report on Friday, May 2nd. Finally, Mizuho reduced their target price on Kura Oncology from $32.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, May 19th. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.50.

Kura Oncology Stock Down 1.1%

Shares of Kura Oncology stock opened at $6.30 on Thursday. The stock has a 50-day moving average price of $6.16 and a 200 day moving average price of $6.76. The company has a market cap of $545.39 million, a P/E ratio of -3.00 and a beta of 0.40. The company has a current ratio of 8.07, a quick ratio of 8.07 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $21.57.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The company had revenue of $14.11 million during the quarter, compared to analysts’ expectations of $39.08 million. As a group, analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.